FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896700797> ?p ?o ?g. }

• W2896700797 endingPage "2337" @default.
• W2896700797 startingPage "2326" @default.
• W2896700797 abstract "The optimal management strategy for children with immune‐tolerant chronic hepatitis B virus (HBV) infection remains unknown. The purpose of this clinical trial was to determine the safety and efficacy of therapy with entecavir and peginterferon in a group of children in the immune‐tolerant phase of HBV infection. Children with immune‐tolerant features of chronic hepatitis B (CHB) received entecavir once‐daily in a dose of 0.015 mg/kg (0.5 mg maximum) for 48 weeks; peginterferon alfa‐2a (180 µg/1.73m 2 subcutaneously) once‐weekly was added at the end of week 8 and continued until week 48. The primary endpoint was lack of detectable hepatitis B e antigen (HBeAg) with HBV DNA levels ≤1,000 IU/mL 48 weeks after stopping therapy. Sixty children (75% female), median age 10.9 (range, 3.4‐17.9) years, were enrolled. All were positive for hepatitis B surface antigen (HBsAg) and HBeAg and had high levels of HBV DNA with normal or minimally elevated levels of alanine aminotransferase (ALT). Fifty‐five children completed the entire 48‐week course of therapy. At 48 weeks after treatment ended (week 96), 2 children (3%) achieved the primary endpoint and were also HBsAg negative and anti–hepatitis B surface antigen antibody (anti‐HBs) positive. One child was HBeAg positive but HBsAg negative at week 60; another was HBeAg negative but HBsAg positive at week 72, which were their last clinic visits. In the remaining children, serum ALT and HBV DNA levels at week 96 were similar to baseline. Thirty‐seven children experienced adverse events (AEs), and 1 had a serious AE (SAE). Conclusion: The combination of entecavir and peginterferon for up to 48 weeks rarely led to loss of HBeAg with sustained suppression of HBV DNA levels in children in the immune‐tolerant phase of HBV infection, and treatment was associated with frequent AEs." @default.
• W2896700797 created "2018-10-26" @default.
• W2896700797 creator A5002446565 @default.
• W2896700797 creator A5024156994 @default.
• W2896700797 creator A5027689213 @default.
• W2896700797 creator A5046642925 @default.
• W2896700797 creator A5055582109 @default.
• W2896700797 creator A5056406094 @default.
• W2896700797 creator A5062967024 @default.
• W2896700797 creator A5084776825 @default.
• W2896700797 creator A5086737230 @default.
• W2896700797 date "2019-02-20" @default.
• W2896700797 modified "2023-09-25" @default.
• W2896700797 title "Combination of Entecavir/Peginterferon Alfa‐2a in Children With Hepatitis B e Antigen–Positive Immune Tolerant Chronic Hepatitis B Virus Infection" @default.
• W2896700797 cites W1503037651 @default.
• W2896700797 cites W1635963002 @default.
• W2896700797 cites W1829641878 @default.
• W2896700797 cites W1937560614 @default.
• W2896700797 cites W1973409404 @default.
• W2896700797 cites W1981406091 @default.
• W2896700797 cites W1996263738 @default.
• W2896700797 cites W1998949869 @default.
• W2896700797 cites W2031317669 @default.
• W2896700797 cites W2041824372 @default.
• W2896700797 cites W2047985134 @default.
• W2896700797 cites W2049354336 @default.
• W2896700797 cites W2060958314 @default.
• W2896700797 cites W2063960105 @default.
• W2896700797 cites W2065939809 @default.
• W2896700797 cites W2073082954 @default.
• W2896700797 cites W2122899893 @default.
• W2896700797 cites W2139876331 @default.
• W2896700797 cites W2149731191 @default.
• W2896700797 cites W2236497981 @default.
• W2896700797 cites W2560241854 @default.
• W2896700797 cites W2755765743 @default.
• W2896700797 cites W2774265441 @default.
• W2896700797 cites W2790022403 @default.
• W2896700797 doi "https://doi.org/10.1002/hep.30312" @default.
• W2896700797 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6465180" @default.
• W2896700797 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30318613" @default.
• W2896700797 hasPublicationYear "2019" @default.
• W2896700797 type Work @default.
• W2896700797 sameAs 2896700797 @default.
• W2896700797 citedByCount "41" @default.
• W2896700797 countsByYear W28967007972019 @default.
• W2896700797 countsByYear W28967007972020 @default.
• W2896700797 countsByYear W28967007972021 @default.
• W2896700797 countsByYear W28967007972022 @default.
• W2896700797 countsByYear W28967007972023 @default.
• W2896700797 crossrefType "journal-article" @default.
• W2896700797 hasAuthorship W2896700797A5002446565 @default.
• W2896700797 hasAuthorship W2896700797A5024156994 @default.
• W2896700797 hasAuthorship W2896700797A5027689213 @default.
• W2896700797 hasAuthorship W2896700797A5046642925 @default.
• W2896700797 hasAuthorship W2896700797A5055582109 @default.
• W2896700797 hasAuthorship W2896700797A5056406094 @default.
• W2896700797 hasAuthorship W2896700797A5062967024 @default.
• W2896700797 hasAuthorship W2896700797A5084776825 @default.
• W2896700797 hasAuthorship W2896700797A5086737230 @default.
• W2896700797 hasBestOaLocation W28967007972 @default.
• W2896700797 hasConcept C126322002 @default.
• W2896700797 hasConcept C147483822 @default.
• W2896700797 hasConcept C203014093 @default.
• W2896700797 hasConcept C203092338 @default.
• W2896700797 hasConcept C2522874641 @default.
• W2896700797 hasConcept C2775940106 @default.
• W2896700797 hasConcept C2776175608 @default.
• W2896700797 hasConcept C2777382497 @default.
• W2896700797 hasConcept C2777410769 @default.
• W2896700797 hasConcept C2777869810 @default.
• W2896700797 hasConcept C2780593183 @default.
• W2896700797 hasConcept C535046627 @default.
• W2896700797 hasConcept C71924100 @default.
• W2896700797 hasConcept C8891405 @default.
• W2896700797 hasConcept C90924648 @default.
• W2896700797 hasConceptScore W2896700797C126322002 @default.
• W2896700797 hasConceptScore W2896700797C147483822 @default.
• W2896700797 hasConceptScore W2896700797C203014093 @default.
• W2896700797 hasConceptScore W2896700797C203092338 @default.
• W2896700797 hasConceptScore W2896700797C2522874641 @default.
• W2896700797 hasConceptScore W2896700797C2775940106 @default.
• W2896700797 hasConceptScore W2896700797C2776175608 @default.
• W2896700797 hasConceptScore W2896700797C2777382497 @default.
• W2896700797 hasConceptScore W2896700797C2777410769 @default.
• W2896700797 hasConceptScore W2896700797C2777869810 @default.
• W2896700797 hasConceptScore W2896700797C2780593183 @default.
• W2896700797 hasConceptScore W2896700797C535046627 @default.
• W2896700797 hasConceptScore W2896700797C71924100 @default.
• W2896700797 hasConceptScore W2896700797C8891405 @default.
• W2896700797 hasConceptScore W2896700797C90924648 @default.
• W2896700797 hasIssue "6" @default.
• W2896700797 hasLocation W28967007971 @default.
• W2896700797 hasLocation W28967007972 @default.
• W2896700797 hasLocation W28967007973 @default.
• W2896700797 hasLocation W28967007974 @default.
• W2896700797 hasOpenAccess W2896700797 @default.
• W2896700797 hasPrimaryLocation W28967007971 @default.

• next